AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ABCL · NASDAQ · Biotechnology

AbCellera Biologics

Discovers antibodies for partners and advances its own clinical candidates.

$11.37

After-hours close+0.03 (+0.24%)

At close$11.35(−8.51%)

Something off on this page? Send us feedback.

Profile

AbCellera Biologics Inc.ABCLHealth Care

Builds antibody medicines through an integrated discovery platform and a growing internal pipeline. Its strategy emphasizes AbCellera-owned assets while selected partner programs remain active.

Combines technology, data science, infrastructure, and interdisciplinary teams to discover and develop antibody-based medicines. The platform historically supported partner programs, including antibodies discovered with Lilly for COVID-19, while the company now advances AbCellera-owned candidates. Its clinical pipeline spans endocrinology, women's health, immunology, and oncology, with ABCL635 and ABCL575 in clinical trials.

Founded in Vancouver, the workforce spans Canada, Australia, and the United States. Founder and CEO Carl Hansen has led the company since inception, and co-founder Véronique Lecault is chief technology officer. The operating model integrates antibody discovery with internal clinical development while selected partner-led programs remain active.

Company facts

CEOCarl L. G. Hansen

ListedDec 11, 2020

ExchangeNASDAQ

HeadquartersVancouver, BC

CountryCanada

Employees562

CIK0001703057

ISINCA00288U1066

Key statistics

Market cap$3.47B

EPS (ttm)−$0.5400

P/E (ttm)−21.02

ROE-17.5%

P/B3.87

P/S52.38

Dividend yield—

Beta2.69vs XLV 1.25

Year to date +231% · Average volume (30d) 8.5M

Analysts

Price target, next 12 months$9.00−20.7%Median of 12 analysts · vs the Aug 28 close

ConsensusBuy11 of 12 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $11.35

High$30.00+164.3%

Median$9.00−20.7%

Low$7.00−38.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 11, 2026	Truist Financial	Target			$29	$30
Aug 6, 2026	Stifel Nicolaus	Target			$8	$9
Jul 7, 2026	Benchmark	Upgrade	Hold	Buy
May 12, 2026	Stifel Nicolaus	Target				$8
May 5, 2026	Cantor Fitzgerald	Target				$7

Earnings

EPS

Estimate−$0.18

ReportedDue Nov 5, 2026

Revenue

Estimate$5.3M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.16	−$0.18	−9.8%	$7.8M	$4.1M	−48.4%	+10.30%
May 11, 2026Q1 FY26	−$0.22	−$0.14	+36.4%	$5.4M	$8.3M	+53.6%	−5.71%
Feb 24, 2026Q4 FY25	−$0.18	−$0.03	+83.3%	$6.7M	$44.9M	+572.9%	−0.93%
Nov 6, 2025Q3 FY25	−$0.17	−$0.19	−11.8%	$6.3M	$9.0M	+41.9%	−13.69%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$4.2M	$17.1M	$9.0M	$44.9M	$8.3M	$4.1M
Gross profit	$4.2M	$17.1M	$9.0M	$36.9M	−$340.0K	$4.1M
Operating income	−$62.7M	−$49.6M	−$76.3M	−$28.6M	−$57.5M	−$62.8M
Net income	−$45.6M	−$34.7M	−$57.1M	−$8.9M	−$43.2M	−$55.4M
Diluted EPS	−$0.15	−$0.12	−$0.19	−$0.03	−$0.14	−$0.18
Gross margin	100.0%	100.0%	100.0%	82.3%	-4.1%	100.0%
Operating margin	-1,479.6%	-290.2%	-851.8%	-63.7%	-691.7%	-1,550.0%

Fiscal years (4-quarter sums)FY21 $375.2M · FY22 $485.4M · FY23 $38.0M · FY24 $28.8M · FY25 $75.1M

Revenue by product · Q2 FY26

Research Fees$3.9M · 96%

Licensing And Royalty Revenue$149.0K · 4%

Revenue by geography · FY25

Canada$64.0M · 85%

United States$11.1M · 15%

Balance sheet, Jun 30, 2026Cash & short-term investments $540.1M · Total debt $135.6M · Total assets $1.31B · Shareholders' equity $896.0M

Dividends

No dividends on record.

Ownership

Institutions 40.70%124.28M sharesInsiders 0.96%2.94M sharesOther 58.34%178.15M shares

Shares outstanding 305.38M · Float 205.09M · 67.2% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Thermopylae Holdings Ltd. · 10 percent owner	56.13M	18.38%	Form 4	Mar 2, 2026
Baker Bros. Advisors LP	33.01M	10.80%	13G	May 7, 2026
Capital World Investors	13.36M	4.38%	13F	May 13, 2026
Two Sigma Investments, LP	10.56M	3.46%	13F	May 15, 2026
TD Waterhouse Canada Inc.	9.56M	3.13%	13F	May 12, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 24, 2026	Michael R. Hayden	director	+53,613	$10.64
Aug 18, 2026	John S. Montalbano	director	+10,000	$11.03
Aug 14, 2026	Andrew Booth	officer: Chief Financial Officer	+37,200	$10.32
Aug 12, 2026	Michael R. Hayden	director	+46,387	$10.37
May 14, 2026	John S. Montalbano	director	+20,000	$4.77